Shutting down JNK signaling resensitizes KRAS G12D-resistant pancreatic cancer cells
- Pancreatic cancer cells that adapt to KRAS G12D inhibition can be pushed back toward sensitivity by suppressing the JNK pathway more completely.
- Selective covalent inhibitors of MAP2K4, MAP2K7, or both were used to probe how much JNK suppression is needed.
- Stronger JNK blockade disables the feedback loop that reactivates KRAS signaling in resistant cells.
- Inhibitor-sensitive cells gain no benefit, so the vulnerability is specific to the resistant state.
💡 Points
If this holds up, the interesting part is the logic: resistance to a KRAS G12D inhibitor runs through JNK feedback, so you hit the node that rewires the pathway, not KRAS again. Covalent engagement of MAP2K4 and MAP2K7 is a neat way to ask how deep the suppression must be, though kinase selectivity between the two will be the real SAR headache. Sparing sensitive cells is the encouraging bit; it's abstract-level so far.